219 related articles for article (PubMed ID: 16275098)
1. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.
Judge A; McClintock K; Phelps JR; Maclachlan I
Mol Ther; 2006 Feb; 13(2):328-37. PubMed ID: 16275098
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.
Semple SC; Harasym TO; Clow KA; Ansell SM; Klimuk SK; Hope MJ
J Pharmacol Exp Ther; 2005 Mar; 312(3):1020-6. PubMed ID: 15525796
[TBL] [Abstract][Full Text] [Related]
3. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
4. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
6. Particle size-dependent triggering of accelerated blood clearance phenomenon.
Koide H; Asai T; Hatanaka K; Urakami T; Ishii T; Kenjo E; Nishihara M; Yokoyama M; Ishida T; Kiwada H; Oku N
Int J Pharm; 2008 Oct; 362(1-2):197-200. PubMed ID: 18586076
[TBL] [Abstract][Full Text] [Related]
7. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
Wang X; Ishida T; Kiwada H
J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
[TBL] [Abstract][Full Text] [Related]
8. Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery.
Ichihara M; Moriyoshi N; Lila AS; Ishida T; Kiwada H
Methods Mol Biol; 2013; 948():35-47. PubMed ID: 23070762
[TBL] [Abstract][Full Text] [Related]
9. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes.
Tagami T; Nakamura K; Shimizu T; Yamazaki N; Ishida T; Kiwada H
J Control Release; 2010 Mar; 142(2):160-6. PubMed ID: 19850094
[TBL] [Abstract][Full Text] [Related]
10. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice.
Ishida T; Ichikawa T; Ichihara M; Sadzuka Y; Kiwada H
J Control Release; 2004 Mar; 95(3):403-12. PubMed ID: 15023452
[TBL] [Abstract][Full Text] [Related]
11. The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine.
Wilson KD; de Jong SD; Kazem M; Lall R; Hope MJ; Cullis PR; Tam YK
J Gene Med; 2009 Jan; 11(1):14-25. PubMed ID: 19003796
[TBL] [Abstract][Full Text] [Related]
12. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
13. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner.
Ishida T; Wang X; Shimizu T; Nawata K; Kiwada H
J Control Release; 2007 Oct; 122(3):349-55. PubMed ID: 17610982
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
U'Ren L; Kedl R; Dow S
Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.
Nagao A; Abu Lila AS; Ishida T; Kiwada H
Int J Pharm; 2013 Jan; 441(1-2):395-401. PubMed ID: 23174409
[TBL] [Abstract][Full Text] [Related]
16. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery.
Abu Lila AS; Uehara Y; Ishida T; Kiwada H
J Pharm Sci; 2014 Feb; 103(2):557-66. PubMed ID: 24347396
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
18. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
Hong M; Zhu S; Jiang Y; Tang G; Pei Y
J Control Release; 2009 Jan; 133(2):96-102. PubMed ID: 18840485
[TBL] [Abstract][Full Text] [Related]
19. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.
Hashimoto Y; Shimizu T; Mima Y; Abu Lila AS; Ishida T; Kiwada H
Toxicol Appl Pharmacol; 2014 May; 277(1):30-8. PubMed ID: 24632081
[TBL] [Abstract][Full Text] [Related]
20. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.
Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 354(1-2):56-62. PubMed ID: 18083313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
